Progressive Structural Brain Abnormalities and Their Relationship to Clinical Outcome

A Longitudinal Magnetic Resonance Imaging Study Early in Schizophrenia

Beng-Choon Ho, MRCPsych; Nancy C. Andreasen, MD, PhD; Peg Nopoulos, MD; Stephan Arndt, PhD; Vincent Magnotta, PhD; Michael Flaum, MD

Background: Many studies have shown that structural brain abnormalities in schizophrenia are already present by the time of index evaluation of first-episode patients. However, whether these abnormalities progressively worsen during the subsequent course of the disorder remains unresolved.

Methods: To study the longitudinal progression of structural brain abnormalities, high-resolution multispectral magnetic resonance images obtained on 73 recent-onset schizophrenic patients and 23 controls were analyzed using state-of-the-art, well-validated, and highly reliable neuroimaging tools. The mean duration between initial and follow-up MRIs was 3 years. Repeated-measures analysis of covariance was carried out to determine (1) whether brain volume changes differed between patients and controls and (2) the significance of regional brain changes on functional outcome in schizophrenia.

Results: We found accelerated enlargement in cortical sulcal cerebrospinal fluid spaces early in the course of schizophrenia. Instead of the usual trajectory of volume enlargement, patients showed progressive reduction in frontal lobe white matter volume. A reciprocal increase in frontal lobe cerebrospinal fluid volume also occurred at a more rapid rate in patients than in controls. In keeping with most of our a priori hypotheses, patients with poor outcome had greater lateral ventricular enlargement over time than patients with good outcome. Progressive decrement in frontal lobe white matter volume and enlargement in frontal lobe cerebrospinal fluid volume were associated with greater negative symptom severity. Reductions in frontal lobe gray and white matter volumes correlated with poorer executive functioning.

Conclusions: There are ongoing changes in the brains of schizophrenic patients during the initial years after diagnosis despite ongoing antipsychotic drug treatment. These progressive changes seem to be most evident in the frontal lobes and to correlate with functional impairment. Disruptions in neurodevelopment or neural plasticity may act alone or in combination to bring about these progressive brain deficits in schizophrenia.

Arch Gen Psychiatry. 2003;60:585-594
tinue during the course of the illness is important for understanding its neurobiological features. Determining whether neural changes continue also has implications for the treatment of schizophrenia. New and more effective treatments will need to be developed if progression occurs despite current treatments.

Perhaps the most robust method to ascertain whether there are progressive neural changes in schizophrenia is through within-subject longitudinal neuroimaging studies. However, such prospective studies are particularly challenging to perform, given the difficulties associated with getting patients and control subjects to return for additional MRIs and the rapid advances in neuroimaging technology. Hence, most longitudinal morphometric MRI studies to date have relatively small sample sizes, use thick, noncontiguous slices that provide poor anatomic resolution, or both.

As a result, findings from these longitudinal neuroimaging studies of schizophrenic patients have been mixed. Early longitudinal computerized tomographic studies (eg, Nasrallah et al) have failed to find progressive enlargement in ventricular size after the onset of schizophrenia. However, more recent longitudinal MRI studies of first-episode patients, and childhood-onset patients seem to provide increasingly convergent evidence that structural brain deficits in schizophrenia may be progressive.

We report herein the results of the largest longitudinal MRI study of schizophrenia conducted to date, to our knowledge, using well-validated and highly reliable state-of-the-art neuroimaging tools. The aims of this study are (1) to determine whether brain volume changes early in the course of schizophrenia differ from the usual age-related trajectory and (2) to determine how brain volume changes may relate to functional outcome in schizophrenia. We measured regional brain volumes during an average of 3 years using high-resolution MRI in a large cohort of schizophrenic patients, many of whom were neuroleptic naive and in the midst of their first episode at the time of initial MRI. These patients were compared with a matched group of control subjects who also underwent serial MRI during the same time. Based on previous longitudinal neuroimaging studies, we hypothesized that (1) greater lateral ventricular enlargement would be associated with poorer outcome in schizophrenia, (2) patients with greater severity of negative symptoms would show greater reductions in frontal lobe volumes over time, (3) severity of psychotic symptoms during follow-up would correlate with longitudinal reductions in temporal lobe volumes, and (4) poor executive functioning at follow-up would be associated with progressive decrement in frontal lobe volumes.

**METHODS**

**PARTICIPANTS**

The study protocol was reviewed and approved by the University of Iowa institutional review board. Seventy-three patients (53 males and 20 females) and 23 control subjects (15 males and 8 females) were recruited through the University of Iowa Mental Health Clinical Research Center. All patients had a *DSM-IV* diagnosis of schizophrenia and were assessed early in the course of schizophrenia with little confounding illness chronicity or previous antipsychotic drug treatment at the time of initial MRI. Forty-one patients (56%) were in the midst of their first psychiatric hospitalization. Thirty-three patients (45%) were neuroleptic naive. The median duration of illness (measured from onset of the first psychiatric symptoms) was 2.0 years (25th and 75th interquartile range, 3.0 years). The median duration of cumulative lifetime antipsychotic drug treatment for the whole patient sample at the time of initial MRI was only 1.0 month (25th and 75th interquartile range, 7.0 months). The clinical characteristics of the patient sample, subdivided by whether they were in the midst of their first psychiatric hospitalization, are summarized in Table 1.

Controls were recruited from the community through newspaper advertisements and were screened using an abbreviated version of the Comprehensive Assessment of Symptoms and History (CASH). Controls were excluded if they had current or past medical, neurological, or psychiatric illnesses. Patient and control groups were comparable with regard to sex, parental socioeconomic status, height, and duration between initial and follow-up MRI (Table 2). Controls were significantly older than patients at initial MRI (mean age difference, 2.38 years; T = 2.06; *P* = .04). Intake and follow-up MRIs were separated by approximately 3 years. The difference in the mean inter-MRI interval between patients and controls (36 days) was not statistically significant (T = 0.27; *P* = .79). All MRIs were obtained between January 1, 1991, and December 31, 2003. The distribution for the year in which MRIs were obtained did not differ significantly between patients and controls (*P* = .93 by Fisher exact test).

**INTAKE AND OUTCOME ASSESSMENTS**

Seventy of the 73 patients in the study were participants in the larger, ongoing Iowa Prospective Longitudinal Study of Recent-Onset Psychoses. The method for selecting and assessing patients has been previously described. At the time of initial MRI, all patients undergo an extensive evaluation, which includes phenomenological assessment (symptoms, family history, and obstetric complications), neurological examination, a neuropsychological battery, and morphometric MRI of the brain. Two structured interview instruments—the *CASH* and the *Psychiatric Status You Currently Have—Baseline Version (PSYCH-BASE)*—are used for clinical assessment. The *Scale for Assessment of Negative Symptoms* and the *Scale for Assessment of Positive Symptoms* form part of the *CASH* and the *PSYCH-BASE*. Psychiatric diagnoses are based on the *CASH*. In addition to interviews with the patients, supplemental information is obtained from collateral sources, including family members and previous medical records.

After intake assessment, participants are evaluated at 6-month intervals with longitudinal follow-up versions of the *CASH* and the *PSYCH-BASE* to develop a retrospective timeline of the severity of symptoms (weekly ratings) and treatment during the preceding 6 months. Additional collateral information is obtained from a family member and available medical records to complete the retrospective timeline. At the 2-, 5-, 9-, and 12-year follow-up evaluations, the extensive assessments performed at intake are repeated, including MRI of the brain and the neuropsychological battery. Data on outcome and treatment during the inter-MRI period were unavailable for the 3 patients who were not participants in this longitudinal study.

Four measures of outcome were examined. Patients were categorized as having poor outcome if they did not achieve remission of positive symptoms in the 6 months preceding follow-up MRI. Remission was operationalized as 8 consecutive...
Table 1. Clinical Characteristics of 73 Schizophrenic Patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>First Hospitalization (n = 41)</th>
<th>Not First Hospitalization (n = 32)</th>
<th>Total (N = 73)</th>
</tr>
</thead>
<tbody>
<tr>
<td>At initial MRI*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at onset of first psychiatric symptoms, mean (SD), y</td>
<td>21.2 (4.87)</td>
<td>21.9 (4.50)</td>
<td>21.5 (4.69)</td>
</tr>
<tr>
<td>Age at first outpatient psychiatric treatment, mean (SD), y</td>
<td>23.0 (5.46)</td>
<td>22.6 (4.67)</td>
<td>22.8 (5.10)</td>
</tr>
<tr>
<td>Age at first psychiatric hospitalization, mean (SD), y</td>
<td>24.1 (5.02)</td>
<td>22.8 (4.34)</td>
<td>23.3 (4.83)</td>
</tr>
<tr>
<td>Previous psychiatric hospitalizations, mean No. (IQR)</td>
<td>0</td>
<td>2.6 (2.59)</td>
<td>1.2 (2.11)</td>
</tr>
<tr>
<td>Duration of illness since first psychiatric symptoms, median (IQR), y</td>
<td>2.0 (4.0)</td>
<td>3.0 (2.5)</td>
<td>2.0 (3.0)</td>
</tr>
<tr>
<td>Duration of previous antipsychotic drug treatment, median (IQR), mo</td>
<td>1.0 (1.0)</td>
<td>8.0 (19.5)</td>
<td>1.0 (7.0)</td>
</tr>
</tbody>
</table>

Abbreviations: IQR, 25th and 75th interquartile range; MRI, magnetic resonance imaging.

*No statistically significant differences between patients in the midst of their first psychiatric hospitalization and those not in their first hospitalization (T2 = 1.18; P = .24, except for number of previous hospitalizations and previous antipsychotic drug treatment: T2 = 4.57; P = .001).

†No statistically significant differences between patients in the midst of their first psychiatric hospitalization and those not in their first hospitalization (T2 = 1.59; P = .12).

‡Severity of 3 or more on any one of the positive symptom global ratings (delusions, hallucinations, formal thought disorder, bizarre behavior, and inappropriate affect).

§Severity of 3 or more on any one of the negative symptom global ratings (alogia, anhedonia, avolition, and affective flattening).

||Sum of global ratings on 5 positive symptoms. |

¶Sum of global ratings on 4 negative symptoms.

Table 2. Demographic Characteristics of 23 Control Subjects and 73 Schizophrenic Patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Controls (n = 23)</th>
<th>Patients (n = 73)</th>
<th>Statistics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males, No. (%)</td>
<td>15 (65)</td>
<td>53 (73)</td>
<td>χ² = 0.46; P = .50</td>
</tr>
<tr>
<td>Parental socioeconomic status, mean (SD)*</td>
<td>2.96 (0.37)</td>
<td>2.92 (0.76)</td>
<td>T1 = 0.33; P = .74</td>
</tr>
<tr>
<td>Height, cm</td>
<td>174.1 (9.08)</td>
<td>174.3 (9.52)</td>
<td>T1 = 0.09; P = .93</td>
</tr>
<tr>
<td>Age at initial MRI, mean (SD) [range], y</td>
<td>26.9 (3.50) [16-35]</td>
<td>24.5 (4.67) [16-35]</td>
<td>T1 = 2.06; P = .04</td>
</tr>
<tr>
<td>Duration of inter-MRI interval, mean (SD) [range], y</td>
<td>3.39 (1.60) [0.92-6.67]</td>
<td>3.29 (1.48) [1.12-6.25]</td>
<td>T1 = 0.27; P = .79</td>
</tr>
</tbody>
</table>

Abbreviation: MRI, magnetic resonance imaging.

*Modified Hollingshead scale.44

weeks during which all 5 positive symptoms were no worse than mild severity (≤2 on global ratings of delusions, hallucinations, positive formal thought disorder, bizarre behavior, and inappropriate affect). Patients who met the criteria for positive symptom remission were categorized as having good outcome. Severity of negative symptoms was the mean weekly ratings of the sum of alogia, anhedonia, avolition, and affective flattening. At initial MRI, controls underwent the same battery of assessments, including the neuropsychological battery. They were invited to return for another assessment 2 to 5 years after initial MRI.

MRI ACQUISITION, PROCESSING, AND MORPHOLOGIC BRAIN MEASURES

Images were obtained using a 1.5-T (Signa; General Electric Medical Systems, Milwaukee, Wis) MRI scanner. Three different MRI sequences were acquired for each participant. The T1-weighted spoiled GRASS (gradient recalled acquisition in the steady state) sequence was acquired with the following parameters: 1.5-mm coronal slices (n = 124); echo time, 5 milliseconds; repetition time, 24 milliseconds; flip angle, 45°; number of excitations, 2; field of view, 26 cm; matrix, 256 x 192; and echo train length, 8. The proton density- and T2-weighted images were acquired with the following parameters: 3-mm coronal slices (n = 60-64); echo time, 36 milliseconds (for proton density) or 96 milliseconds (for T2); repetition time, 3000 milliseconds; number of excitations, 2; field of view, 26 cm; matrix, 256 x 192; and echo train length, 8. All MRIs were rated for overall quality and for movement artifacts using a scale from 0 (very poor) to 4 (excellent). All MRIs in this study received quality ratings between good and excellent.

Image processing was performed on a computer workstation (Silicon Graphics Inc, Mountain View, Calif) using the lo-
cally developed BRAINS (Brain Research: Analysis of Images, Networks, and Systems) software package. Detailed descriptions of image analysis methods are provided elsewhere. To briefly, the T1-weighted images were spatially normalized and resampled so that the anterior-posterior axis of the brain was realigned parallel to the anterior-posterior commissure line, and the interhemispheric fissure was aligned on the other 2 axes. The T2- and proton density–weighted images were aligned to the spatially normalized T1-weighted image using an automated image registration program. These images were then warped into standardized stereotactic Talairach atlas space to generate automated measurements of the frontal, temporal, parietal, and occipital lobes; cerebellum; and subcortical regions. To further classify tissue volumes into gray matter (GM), white matter (WM), and CSF, we used a discriminant analysis method of tissue segmentation based on automated training class selection that used data from the T1, T2, and proton density sequences. This method allowed us to identify the range of values that characterized GM, WM, and CSF in our multispectral data (10-70 for CSF, 70-190 for GM, and 190-250 for WM). Each voxel was given an intensity value that was based on the weights assigned by the discriminant function and that reflected the relative combination of GM, WM, and CSF in a given voxel that allowed us to correct for partial volume. Intraclass correlations for this automated tissue segmentation analysis ranged from 0.97 to 0.98. Regions of interest (ROIs) examined in the patient-control comparison included total brain tissue volume; lateral ventricle volume; cortical sulcal CSF volume; tissue and CSF volumes for the frontal, temporal, and parietal lobes; and cerebellar tissue volume.

STATISTICAL ANALYSIS
To investigate the first aim of the study, repeated-measures analysis of covariance (ANCOVA) was used to examine whether diagnostic grouping (patients vs controls) had significant interactions with longitudinal within-subject changes in each ROI. Intake and follow-up volumes for each ROI were the dependent measures (within-subject factors). The independent measure in each general linear statistical model was diagnostic grouping (patients vs controls), changes in these ROIs over time expressed as a percentage of baseline volume was statistically significant at P < .05. All statistical tests were 2-tailed.

Last, to ascertain the effects of antipsychotic drug treatment and whether this treatment may be a confounder on within-patient changes in brain volumes, exploratory analyses using repeated-measures ANCOVAs were performed with cumulative antipsychotic drug dose, total antipsychotic drug treatment duration, percentage of time treated with typical antipsychotic agents, and percentage of time treated with atypical antipsychotic agents separately as independent variables (age, sex, height, and inter-MRI interval were similarly entered as covariates).

RESULTS
LONGITUDINAL WITHIN-SUBJECT CHANGES IN ROIs BETWEEN CONTROLS AND PATIENTS
To evaluate whether volumetric changes over time differed between controls and patients, the effect of diagnostic grouping on within-subject change in each ROI was tested using repeated-measures ANCOVA (Table 3). Longitudinal changes in cortical sulcal CSF, frontal lobe tissue, and frontal lobe CSF volumes differed significantly between patients and controls. Patients showed greater within-subject increases in cortical sulcal CSF volumes than controls (F1,90=4.16; P = .04) (Table 3). The mean (SD) rate of increase in cortical sulcal CSF volume (expressed as a percentage of baseline volume) was 6.6% (10.87%) per year in patients vs −1.3% (9.01%) per year in controls (Figure 1A).

Frontal lobe tissue volume increased over time in controls, whereas patients showed a mean decrease (F1,90=3.89; P = .05) (Table 3). The reciprocal increase in frontal lobe CSF volume in patients was significantly larger than that in controls (F1,90=10.13; P = .002). The mean (SD) rates of change in frontal lobe CSF volume were −1.4% (11.46%) per year in controls and 9.1% (12.71%) per year in patients (Figure 1C). Mean (SD) frontal lobe tissue volume increased by 0.8% (1.46%) per year in controls, and patients showed a decline of 0.2% (1.63%) per year (Figure 1B). This differential change in frontal lobe tissue volume was further explored by examining GM and WM volumes. Patients had a mean (SD) reduction in frontal lobe WM volume from 174.6 (19.61) cm³ at the intake MRI to 173.6 (19.93) cm³ at the follow-up MRI compared with an increase in controls from 186.9 (22.24) cm³ at the intake MRI to 191.1 (24.08) cm³ at the follow-up MRI (within-subject effect of diagnostic grouping, F1,90=5.57; P = .02). Mean (SD) changes in frontal lobe GM volume did not differ significantly between patients (intake MRI, 266.7 [24.50] cm²; follow-up MRI, 266.4 cm²).
Patients (n = 73)

At initial MRI, patients had significantly smaller total brain volumes (Table 3).

There were no differential changes between patients and controls regarding total brain tissue, lateral ventricles, temporal lobe tissue, temporal lobe CSF, parietal lobe tissue, parietal lobe CSF, or cerebellar tissue volumes (Table 3).

### CROSS-SECTIONAL BETWEEN-GROUP DIFFERENCES IN ROIs

At initial MRI, patients had significantly smaller total brain tissue volume ($F_{1,95} = 8.37; P = .005$), smaller frontal lobe tissue volume ($F_{1,95} = 7.53; P = .007$), smaller temporal lobe tissue volume ($F_{1,95} = 6.77; P = .01$), and smaller cerebellar tissue volume ($F_{1,95} = 4.27; P = .04$) than controls. No statistically significant differences were found in lateral ventricles, cortical sulcal CSF, frontal lobe CSF, temporal lobe CSF, parietal lobe tissue, or parietal lobe CSF volumes between patients and controls at initial MRI ($F_{1,95} = 3.00$ and $P = .09$ for all).

At follow-up MRI, patients had significantly smaller total brain tissue volume ($F_{1,97} = 9.17; P = .003$), smaller frontal lobe tissue volume ($F_{1,97} = 12.08; P < .001$), smaller temporal lobe tissue volume ($F_{1,97} = 6.94; P = .01$), and smaller parietal lobe tissue volume ($F_{1,97} = 4.60; P = .03$) than controls. No statistically significant differences were found in lateral ventricles, cortical sulcal CSF, frontal lobe CSF, temporal lobe CSF, parietal lobe CSF, or cerebellar tissue volumes between patients and controls at follow-up MRI ($F_{1,97} = 1.49$ and $P = .22$ for all).

### RELATIONSHIPS BETWEEN LONGITUDINAL VOLUMETRIC CHANGES AND OUTCOME

Based on the absence of positive symptom remission in the 6 months preceding follow-up MRI, 27 (39%) of 70 patients were categorized as having poor outcome. Outcome grouping had a significant effect on within-subject change in lateral ventricle volume ($F_{1,64} = 3.86; P = .05$). Patients with poor outcome had greater mean (SD) ventricular enlargement over time (3.7% [6.46%] per year) vs those with good outcome (0.9% [6.09%] per year) (Figure 2A).

There were significant effects of negative symptom severity on within-subject changes in frontal lobe WM ($F_{1,64} = 8.16; P = .006$) and frontal lobe CSF ($F_{1,64} = 3.99; P = .05$) volumes but not in frontal lobe GM volume ($F_{1,64} = 1.19; P = .28$). Greater negative symptom severity during the inter-MRI interval was associated with greater decline in frontal lobe WM volume (Pearson $r = .31; n = 70; P = .01$) (Figure 2B) and with greater enlargement in frontal lobe CSF volume (Pearson $r = 0.44; n = 70; P < .001$) (Figure 2C). There were no significant effects of positive symptom severity on longitudinal changes in temporal lobe tissue or temporal lobe CSF volumes ($F_{1,64} = 1.48$ and $P = .23$ for all).

The fourth measure of outcome was executive functioning assessed using a summed $z$ score average of 7 variables from the neuropsychological battery administered at the time of follow-up MRI. As a group, patients had mild impairment in executive functioning at the time of follow-up (mean [SD] $z$ score = -0.62 [0.76]). There was a significant effect of executive functioning on within-subject changes in frontal lobe GM volume ($F_{1,67} = 4.97; P = .03$) and on frontal lobe WM volume ($F_{1,67} = 4.32; P = .04$). Impairment in executive functioning was associated with longitudinal reductions in frontal lobe GM and WM volumes (Pearson $r = 0.26$ and 0.24, respectively; $n = 72; P = .04$) (Figure 2D and E). There were no significant effects of executive functioning on frontal lobe CSF volume ($F_{1,67} = 1.06; P = .31$).
the study, patients received antipsychotic drug treatment for most of the time between MRIs (mean 83.5% of inter-MRI duration). Thirty-eight patients received antipsychotic drug treatment throughout the entire inter-MRI interval: 7 patients received typical antipsychotic drug treatment only, 20 received the newer atypical antipsychotic agents only, and 11 received combinations of typical and newer atypical antipsychotic medications. Fifteen patients had required treatment with clozapine. The sample was mostly treated with the newer atypical antipsychotic agents during the inter-MRI interval (mean [SD] duration of treatment with newer atypical antipsychotic agents, 61.7% [38.9%] of antipsychotic drug treatment duration; of treatment with typical antipsychotics, 27.7% [34.6%]; and of treatment with clozapine, 10.6% [23.7%]). The mean (SD) total cumulative antipsychotic drug dose during the inter-MRI period was 556 ± 117.1 (494 ± 284.5) chlorpromazine-mg equivalents, or 462.2 ± 187.5 chlorpromazine-mg equivalents per day. Antipsychotic drug treatment compliance was generally good (mean [SD], 1.90 ± 0.81; rated on a 5-point scale: 1 indicates excellent; 2, good; 3, fair; 4, poor; and 5, noncompliant).

To ascertain whether antipsychotic medication treatment may be a confounder on within-patient changes in brain volumes, repeated-measures ANCOVAs were examined with cumulative antipsychotic drug dose as the independent variable (age, sex, height, and inter-MRI interval were similarly entered as covariates). The same analysis was repeated separately with total antipsychotic drug treatment duration, percentage of time treated with typical antipsychotic drugs, and percentage of time treated with atypical antipsychotic drug as the independent variable. There were no significant effects from these 4 treatment measures on any of the ROIs (F<sub>1,65</sub> = 2.64; P = .11).

Figure 1. Mean within-subject changes in brain regions in which patients and controls differed significantly. Volume change is calculated as follow-up minus baseline expressed as a percentage of baseline volume per year. A, Cortical sulcal cerebrospinal fluid (CSF) volume increased in patients and decreased in controls (6.6% per year vs −1.3% per year; F<sub>1,90</sub> = 4.16; P = .04). B, Frontal lobe tissue volume increased in controls and decreased in patients (9.1% per year vs –1.4% per year; F<sub>1,90</sub> = 10.13; P = .002). C, Frontal lobe CSF volume increased in patients and decreased in controls (10.1% per year vs −2.5% per year; F<sub>1,90</sub> = 3.89; P < .05).

This is the largest study to date, to our knowledge, using serial high-resolution MRIs to assess whether longitudinal structural brain changes in schizophrenia differ from the usual age-related trajectory. We found accelerated enlargements in cortical sulcal CSF spaces early in the course of schizophrenia. Instead of the usual trajectory of volume enlargement, patients showed progressive decrement in frontal lobe WM volume over time. A reciprocal increase in frontal lobe CSF volume also occurred at a more rapid rate than in controls. These brain volume changes seem to be most evident in the frontal lobes, and they correlate with functional impairment. Progressive decrement in frontal lobe WM volume and enlargement in frontal lobe CSF volume were associated with greater negative symptom severity, and reductions in frontal lobe GM and WM volumes correlated with poorer executive functioning. Patients with poor outcome (ie, those without remission of positive symptoms) had greater lateral ventricular enlargement over time than those with a good outcome. Longitudinal changes in temporal lobe volumes, however, did not predict positive symptom severity, as we had hypothesized a priori.

To the best of our knowledge, no previous longitudinal MRI studies have reported progressive cortical sulcal CSF volume enlargement in schizophrenic patients. Enlargements in CSF volume over time may be indicative of progressive brain tissue volume reduction. Intracranial volume is stable after fusion of the cranial sutures, and CSF fills in for brain tissue loss. However, longitudinal changes in total brain tissue volume in our study did not differ significantly between patients and controls, although patients had significantly greater enlargements in cortical sulcal CSF volume over time. The finding that schizophrenic patients show greater pro-
gressive reduction in total brain tissue volume than controls is somewhat mixed among the longitudinal neuroimaging studies to date. Two prospective longitudinal studies on first-episode schizophrenic patients have reported a differential reduction in total brain tissue volume, but other studies, including the present study, have not found patients to differ from controls. The study by Cahn et al on first-episode schizophrenia over a 1-year period and a series of studies on childhood-onset schizophrenic patients have found progressive reductions in total GM volume in schizophrenic patients. Similar to total brain tissue volume, the finding of progressive enlargement in lateral ventricular volume during follow-up has been similarly contradictory. Some studies have reported progressive ventricular enlargement, whereas others including this study, have not.

Indeed, the literature on progressive volumetric brain changes during the longitudinal course of schizophrenia seems to be conflicting, and no 2 (longitudinal) studies have found the same pattern of changes across all of these measures, and each study seems to have its own

Figure 2. Relationships between longitudinal changes in brain volumes and outcome in schizophrenia. Volume change is calculated as follow-up minus baseline expressed as a percentage of baseline volume per year. A, Lateral ventricular volume enlargement was significantly greater in patients with poor outcome than in those with good outcome (3.7% per year vs 0.9% per year; F_{1,64}=3.86; P=.05). B, Greater negative symptom severity was significantly correlated with a greater reduction in frontal lobe white matter (WM) volume (Pearson r =−0.31; n=70; P=.01). C, Greater negative symptom severity was significantly correlated with greater enlargement in frontal lobe cerebrospinal fluid (CSF) volume (r=0.44; N=70; P<.001). D, Impairment in executive functioning was associated with a greater reduction in frontal lobe gray matter (GM) volume (r=0.26; n=72; P=.03). E, Impairment in executive functioning was associated with a greater reduction in frontal lobe WM volume (r=0.24; n=72; P=.04).
unique combination of results. However, although individual studies may report different combinations of subregions undergoing progressive volumetric changes, the growing list of longitudinal MRI studies in first-episode patients,6-22 chronic patients,21 and childhood-onset patients22-27 provides increasingly convergent evidence that structural brain deficits in schizophrenia may be progressive. Several factors may have led to this “unique combination of results” in each of these longitudinal studies: heterogeneity of schizophrenia, differences in imaging parameters, image analysis and processing, reproducibility of repeated MRIs, and small sample size with inadequate power.

Although our study has the largest sample to date, it has its own limitations as well. Comparatively fewer controls than schizophrenic patients, an older control group, variability in inter-MRI interval, and naturalistic, nonstandardized antipsychotic drug treatment may have affected our findings. Although controls were significantly older than patients, it is unlikely that a mean difference of 2.4 years during early adulthood would affect longitudinal changes in brain volumes between patient and control groups. Furthermore, the distributions of patients and controls by decade of age (ie, 16-25 years and 26-35 years) were no different, and there were no significant age at initial MRI × inter-MRI interval interaction effects on within-subject changes in brain volumes. Age at intake MRI and inter-MRI interval were entered as covariates in our analyses to statistically “control” for these differences. We also explored the potential effect of antipsychotic treatment on longitudinal changes in brain volumes, and we did not find any significant effects from any of the 4 antipsychotic drug treatment measures.

In this study, longitudinal brain morphologic changes early in the course of schizophrenia seem to be most evident in the frontal lobes. Schizophrenic patients had a mean reduction in frontal lobe WM volume and a concomitant increase in frontal lobe CSF volume over time. Controls, on the other hand, showed an increase in frontal lobe WM volume. This differential change may represent a dysmaturation process in schizophrenia, in which frontal lobe WM fails to undergo the usual trajectory of progressive myelination or increased interconnection. Previous in vivo MRI studies35,68 have indicated that cerebral WM volume increases during childhood. Normal central nervous system development proceeds in a systematic spatial sequence,5,50 such that the frontal lobes are one of the last regions to mature.51 Cerebral WM development extends into adulthood,68 and frontal lobe WM volume may peak as late as in the fifth decade of life in healthy individuals.52 This increase coincides with the period when profound cognitive development is taking place and may result from myelination or increased interconnectivity between cerebral regions. Myelin sheath thickness and the number of myelin lamellae have been reported to increase with age in primate brains, suggesting that oligodendrocytes actively produce myelin during the normal aging process.3,53 Although we are beginning to better understand these late maturation events in the central nervous system, the pathogenetic changes and mechanisms that underlie the progressive frontal lobe WM volume reduction in schizophrenia are unclear. Defects in oligodendrocytes and myelin lamellae reported in the prefrontal cortex of schizophrenic patients54-56 may explain this progressive decrement in frontal lobe WM volume. There is also an emerging body of literature from MRI spectroscopy and diffusion tensor imaging studies5-7 implicating WM abnormalities in schizophrenia.

Our findings also indicate that progressive changes in brain volumes, again predominantly in the frontal lobes, correlate with functional outcome in schizophrenia. Patients with a more severe and enduring form of the disorder were more likely to show longitudinal alterations in brain volumes. We replicated the association between poor positive symptom remission and progressive lateral ventricular enlargement, which has been reported in previous longitudinal MRI studies.18,20,28,59 In addition, we found that greater negative symptom severity correlated with longitudinal reduction in frontal lobe WM volume and progressive enlargement in frontal lobe CSF volume. Patients with poor executive functioning at follow-up showed greater declines in frontal lobe GM and WM volumes over time. These functional correlates for longitudinal reductions in frontal lobe WM and GM volumes are consistent with those of previous cross-sectional MRI studies.60-66

What is the mechanism that produces these progressive changes? During the past 15 years, one of the most prevailing theories regarding the pathogenesis of schizophrenia has been that it is a neurodevelopmental disorder. This hypothesis posits that abnormal genetic or epigenetic factors interfere with early brain development (neurulation, cellular proliferation, migration, differentiation, and synaptogenesis).67,68 Later brain developmental processes (eg, apoptosis and synaptic pruning) or other neuropathological events (eg, stress) interact with the already aberrant neuropathological events to result in symptoms and signs of schizophrenia.

Although a large body of literature has been regarded as evidence for the neurodevelopmental hypothesis,69 certain aspects of schizophrenia, including progressive brain changes of the magnitude observed in the present study, may be difficult to attribute to aberrant neurodevelopment.70 Changes that progress over time are usually considered to represent “neurodegeneration” or “atrophy,” as originally posited by Kraepelin et al71 when they identified this illness and called it “dementia praecox.” However, gliosis, considered to be the hallmark of neuronal death in neurodegenerative disorders, is characteristically absent in schizophrenia. Absence of gliosis has been the strongest evidence against considering schizophrenia to have a neurodegenerative component. One alternative model that may explain our results is that of a “progressive neurodevelopmental disorder.”1,69 According to this model, schizophrenia occurs as a consequence of multiple aberrations in the process of brain development, with some occurring during fetal life or early childhood (“early neurodevelopment”), whereas others occur during adolescence and young adulthood (“late neurodevelopment”). Our data suggest that the late neurodevelopmental mechanisms, which were already active during the months before the onset of clinical symptoms, may continue to exert their damaging effects after
onset and during the early years of the illness, which characteristically is a chronic lifetime condition. The developmental neurobiological processes that explain these serial changes remain a puzzle, however.

Given that brain changes continue to progress and tissue loss persists, the search for treatments that may arrest progression assumes great importance. Our findings indicate that current treatments do not arrest the progression of the illness. Ongoing changes occur in the brains of schizophrenic patients during the initial years after diagnosis, even when they had received antipsychotic drug treatment during much of that period. Although antipsychotic drug therapy reduces the risk for relapse of psychotic symptoms, whether these medications actually modify other aspects of the course of schizophrenia remains a topic of debate. The results of the present study indicate that the medications currently used cannot modify an injurious process occurring in the brain, which is the underlying basis of symptoms and other aspects of outcome and should be the ultimate target of treatment. We found that progressive volumetric brain changes were occurring despite ongoing antipsychotic drug treatment.

Although it is reasonable to assume that longitudinal volumetric changes result primarily from ongoing pathogenetic process(es) of the illness, it is important to consider other causes not directly related to the neurobiology of schizophrenia. Differences arising from chronic illness, including poor nutrition, fluid imbalance, and diminished social and environmental stimuli, may be potential mediators for longitudinal brain changes as well. The brain, much like other organ systems, responds to environmental effects, and neuroplastic changes occur throughout life. Therefore, the longitudinal volumetric changes observed in our study probably resulted from a combination of factors. In addition, given the heterogeneity of schizophrenia, different pathogenetic processes may be associated with the progressive volumetric changes in different patients.

In conclusion, our findings suggest that there are ongoing changes in the brains of schizophrenic patients during the initial years after diagnosis despite concurrent antipsychotic drug treatment. Progression in volumetric deficits seems to be most prominent in the frontal lobes. Late developmental processes and neural plasticity may act alone or in combination with disrupted early neurodevelopment to bring about such progressive brain changes in schizophrenia.

Submitted for publication June 14, 2002; final revision received December 31, 2002; accepted January 9, 2003.

This study was supported in part by grants MH631593, MH40856, and MH43271 from the National Institute of Mental Health, Bethesda, Md.

This study was presented in part at the 40th Annual Meeting of the American College of Neuropsychopharmacology; December 9, 2001; Waikoloa, Hawaii; and at the XI Biennial Winter Workshop on Schizophrenia; February 23, 2002; Davos, Switzerland.

Corresponding author and reprints: Beng-Choon Ho, MRCPsych, Department of Psychiatry, University of Iowa College of Medicine, 200 Hawkins Dr, Iowa City, IA 52252 (e-mail: beng-ho@uiowa.edu).
33. Andreasen NC.


73. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17:325-351.


